Australia markets closed

PYC Therapeutics Limited (PYC.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.0810+0.0010 (+1.25%)
At close: 04:10PM AEDT
Full screen
Previous close0.0800
Open0.0830
Bid0.0810 x 42340100
Ask0.0830 x 21464600
Day's range0.0800 - 0.0830
52-week range0.0500 - 0.1150
Volume444,040
Avg. volume1,218,755
Market cap305.962M
Beta (5Y monthly)0.63
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • PR Newswire

    PYC'S FOURTH DRUG CANDIDATE HAS DISEASE-MODIFYING POTENTIAL IN POLYCYSTIC KIDNEY DISEASE

    PYC Therapeutics today announces the results of a study conducted in human 3-dimensional models derived from patients with end-stage renal failure due to Autosomal Dominant Polycystic Kidney Disease (PKD). The results demonstrate that an investigational drug candidate designed by PYC (known as PYC-003) to address this disease at its root cause is effective. These 3D patient-derived cyst models represent the 'gold-standard' pre-clinical assay for evaluating drug candidates in this indication[8].

  • PR Newswire

    US FDA DESIGNATES PYC'S LEAD AS A FAST TRACK DEVELOPMENT PROGRAM

    PYC Therapeutics Limited (ASX:PYC) today announces that the VP-001 program, the first investigational drug candidate designed to address Retinitis Pigmentosa type 11 (RP11) to progress to human trials, has received Fast Track designation from the US Food and Drug Administration (FDA).